How to Cite: Ahmad, B., Ahmad, S., Inayat, K., Bilal, S. S., Arbab, A., & Khan, U. A. (2023). Tolerance of sorafenib in patients with residual HCC post TACE. International Journal of Health Sciences, 6(S10), 1427–1434. https://doi.org/10.53730/ijhs.v6nS10.14038 International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2023. Manuscript submitted: 09 Nov 2022, Manuscript revised: 18 Jan 2023, Accepted for publication: 27 Feb 2023 1427 Tolerance of sorafenib in patients with residual HCC post TACE Dr. Bilal Ahmad Senior Registrar Medical Oncology, Kuwait Teaching Hospital Peshawar, Pakistan Dr. Sohail Ahmad Specialist Registrar Medical Oncology, Hayatabad Medical Complex Peshawar, Pakistan Corresponding author email: sohail.a601@gmail.com Dr. Kashmala Inayat Medical Officer, Health department KPK, Pakistan Dr. Syeda Sama Bilal Medical Officer, Health department KPK, Pakistan Dr. Anna Arbab Medical Officer, Health department KPK, Pakistan Dr. Umar Ali Khan PGR, Diagnostic Radiology, NWGH, Pakistan Abstract---Background: Hepatocellular carcinoma (HCC) is among the most prevalent cancers and the second leading cause of cancer- related mortality globally. Objective: The aim was to investigate the sensitivity of sorafenib administration after TACE in advanced HCC patients. Methods: From June 2021 to June 2022, 36 patients from Hayatabad Medical Complex Peshawar were enrolled in this retrospective research. Based on the correct state of liver activity, sorafenib medication was started within two weeks of finishing TACE treatment. Throughout each follow-up, the liver and kidney function, adverse effects, and medicinal impact were assessed using the Modified response assessment criteria in solid tumors (mRECIST). Results: The mean overall survival (mOS) and mean time to progress (mTTP) were 11.5 months and 7.5 months, respectively. Patients with one or more localised hepatic lesions were respectively 18 months and 12 months old ( 2 = 4.613, P = 0.0314). No patients had a full response, three had partial responses, 11 had stable disease (SD), and 22 had progressive illness (PD), as per the mRECIST. The disease control rate (DCR) was 38.89% (14/36) and the response rate was